+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column



Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column



Current Pharmaceutical Design 9(4): 307-321



The administration of steroids is not always effective for the treatment of ulcerative colitis (UC). Their long-term use often causes adverse effects which sometimes result in their stoppage and acute exacerbation. Therefore, an alternative treatment is necessary in order to decrease steroid dosage and avoid the clinical problems associated with steroids. Methods The effectiveness and adverse effects of a leukocytapheresis (LCAP) were investigated in a controlled multicenter trial with randomized assignment of 76 active-stage UC patients in two groups. In the LCAP group (39 patients), LCAP weekly for 5 weeks as an intensive therapy was added to the on-going drug therapy, while steroids were maintained but not increased, and then LCAP was gradually reduced to once every 4 weeks as a maintenance therapy. In the high dose prednisolone (h-PSL) group (37 patients), PSL was added or increased 30 approximately 40 mg/day for moderately severe and 60 approximately 80 mg/day for severe patients and then gradually tapered. Findings The LCAP group showed a significantly higher effectiveness (74% vs. 38%; p=0.005) and lower incidence of adverse effects (24% vs. 68%; p<0.001). The patients were able to continue the trial for a longer period in the LCAP group than the h-PSL group (p=0.012). Clinical activity and endoscopic indexes showed the LCAP group had better improvements than the h-PSL group. Interpretation The results of the trial show that LCAP permits a reduction in total PSL dosage and is more effective and safer than high-dose PSL administration for intensive therapy, and LCAP may maintain remission longer than PSL.

(PDF emailed within 1 workday: $29.90)

Accession: 035349899

Download citation: RISBibTeXText

PMID: 12570823


Related references

Multicenter randomized double blind controlled trial for ulcerative colitis therapy with leukocytapheresis. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No 542, 2003

Efficacy of Vedolizumab in Ulcerative Colitis by Prior Treatment Failure in GEM-INI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Inflammatory Bowel Diseases 18: S25-S26, 2012

Prospective multicenter randomized study of leukocytapheresis using filter method for ulcerative colitis. Gastroenterology 116(4 PART 2): A813, April, 1999

Efficacy of Vedolizumab in Ulcerative Colitis by Prior Treatment Failure in GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Inflammatory Bowel Diseases 18: S1-S2, 2012

Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy 28(1): 67-74, 2016

Efficacy of Indigo naturalis in a Multicenter Randomized Controlled Trial of Patients with Ulcerative Colitis. Gastroenterology: -, 2017

Multicenter, randomized, double blind, placebo controlled trial of deligoparin for active ulcerative colitis. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No 539, 2003

Controlled, open, randomized multicenter trial comparing the effects of treatment on quality of life, safety and efficacy of budesonide foam and betamethasone enemas in patients with active distal ulcerative colitis. Hepato-Gastroenterology 51(59): 1345-1349, 2004

Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis--results of a randomized pilot trial. Digestive Diseases and Sciences 52(9): 2044-2053, 2007

Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clinical Gastroenterology and Hepatology 4(12): 1502-1506, 2006

Efficacy and tolerability of new 5-ASA formulation rectal foam In active distal ulcerative colitis A multicenter controlled randomized trial. Gastroenterology 108(4 SUPPL ): A857, 1995

A multicenter study of the efficacy and safety of leukocytapheresis therapy without concomitant systemic steroid treatment in patients with active ulcerative colitis. Transfusion and Apheresis Science 44(2): 113-117, 2011

A novel nutritional formula reduces corticosteroid requirements in patients with ulcerative colitis A prospective, double-blinded, randomized, placebo controlled multicenter trial. Gastroenterology 118(4 Suppl 2 Part 1): AGA A782, April, 2000

Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. American Journal of Gastroenterology 100(6): 1362-1369, 2005

Oral 5-aminosalicylic acid therapy for the prevention of relapse in patients with ulcerative colitis during remission A new therapeutical approach by using 5-ASA tablets 800 MG A multicenter controlled randomized trial. Gastroenterology 110(4 SUPPL ): A1030, 1996